SPY326.97-3.68 -1.11%
DIA271.44-5.08 -1.84%
IXIC10,778.80-14.48 -0.13%

AVITA Therapeutics Announces First Patient Enrolled In Pivotal Study Evaluating RECELL System For Repigmentation Of Stable Vitiligo

AVITA Therapeutics, Inc. (NASDAQ:RCEL, ASX:AVH)))), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet

· 09/14/2020 08:06

AVITA Therapeutics, Inc. (NASDAQ:RCEL, ASX:AVH))))), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the initiation of the pivotal study assessing the use of the RECELL® System to treat stable vitiligo with the enrollment of the first patient at Miami Dermatology and Laser Institute in Miami, FL. The study will evaluate the safety and effectiveness of AVITA Therapeutic's RECELL System to repigment skin in patients who have vitiligo that has been stable for at least one year.